Posts

Posted on

BevCanna Partners with Naturo to Launch Beyond Energy All-Natural Hemp Energy Drink

BevCanna Partners with Naturo to Launch Beyond Energy All-Natural Hemp Energy Drink

Partnership with Naturo to bring access to over 3,000 points of distribution as well as significant retail and manufacturing expertise, with all necessary licenses already in place

VANCOUVER, British Columbia–(BUSINESS WIRE)–
Emerging leader in infused innovations BevCanna Enterprises Inc. (“BevCanna” or the “Company”) (CSE:BEV, OTCQB:BVNNF, FSE:7BC), is excited to announce the development of a new Beyond Energy all-natural hemp energy drink. Launched in partnership with experienced beverage company, Naturo Group, the beverage will be sold under BevCanna’s flagship house brand, Anarchist Mountain Beverages™.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201112005424/en/

Beyond Energy natural hemp energy drink (Photo: Business Wire)

Beyond Energy natural hemp energy drink (Photo: Business Wire)

Formulated with natural mineral spring water, Beyond Energy features all-natural vegan friendly ingredients, including natural yuzu and lime flavours, caffeine from natural tea, ginseng, B & D vitamins, and hemp seed extract, which is a functional source of omegas and promotes brain function and overall wellbeing. Additionally, the presence of essential B and D vitamins such as B12 and D3 combats a global vitamin deficiency within consumers today. The innovative fortified hemp seed extract formulation does not require Health Canada cannabis licensing and will allow the beverage to be sold in traditional mass retail points of distribution and through direct to consumer e-commerce channels.

“The launch of the Beyond Energy beverage will not only expand BevCanna’s Anarchist Mountain brand into traditional points of retail and ecommerce, but will also allow BevCanna to sell product into Naturo’s extensive retail distribution network,” said John Campbell, CSO of BevCanna.

Naturo Group offers a full service white-label beverage manufacturing vertical for traditional CPG clients and owns and operates nationally distributed house brands across Canada. Naturo’s house brand beverages are currently sold in more than 3000 Canadian retailers, including 7/11, Loblaws, London Drugs, Metro and Farm Boy, as well as online direct-to-consumers, via Amazon; and is expanding into the U.S. market in 2021. Naturo’s significant and established distribution network will allow BevCanna to scale its retail distribution quickly and to leverage this network for its range of infused beverages.

“Naturo has been exceptionally successful in growing its retail and e-commerce distribution network, along with its robust manufacturing capabilities,” said Marcello Leone, Founder of Naturo Group & CEO of BevCanna “Now that the market for cannabis and hemp-derived beverages is exploding, Naturo is excited to further strengthen it’s relationship with BevCanna to launch these innovative new natural products through Naturo’s robust manufacturing and distribution network, and for continued collaboration with BevCanna.”

Beyond Energy will represent the first beverage to launch under the Anarchist Mountain banner in traditional sales channels. The Anarchist Mountain brand represents iconic West Coast attributes in all aspects of its brand identity and is formulated based on extensive consumer trends research. Inspired by the site of BevCanna’s bottling operations and pristine alkaline spring water source in the BC interior, Anarchist Mountain is a nod to the rich history of cultivation in the iconic region – both a longstanding legacy and notoriety within cannabis, and the 100+ wineries spread throughout the region.

The full Anarchist Mountain brand portfolio will include non-cannabinoid options, including Beyond Energy, which will use hemp seed extract, and which will be sold through traditional retail and ecommerce; as well as cannabis-infused options, which will be sold through licensed dispensaries. As domestic and international markets evolve regulations to allow for a broader distribution of cannabinoid based products, BevCanna will leverage the distribution network established through the non-cannabinoid options to broaden the distribution for cannabinoid infused beverages, consistent with their overall growth strategy of scaling into traditional points of retail to the maximize addressable market and leverage brand equity.

About BevCanna Enterprises Inc.

BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) develops and manufactures cannabinoid–infused beverages and consumer products for in–house brands and white label clients. With decades of experience creating, branding and distributing iconic brands that have resonated with consumers on a global scale, the team demonstrates an expertise unmatched in the emerging cannabis beverage category. Based in British Columbia, Canada, BevCanna owns the exclusive rights to a pristine spring water aquifer, access to a world–class 40,000–square–foot, HACCP certified manufacturing facility, with a current bottling capacity of up to 210M bottles per annum. BevCanna also recently acquired US natural health and wellness e-commerce platform Pure Therapy. BevCanna’s vision is to be a global leader in infused innovations.

On behalf of the Board of Directors:

John Campbell, Chief Financial Officer and Chief Strategy Officer

Director, BevCanna Enterprises Inc.

Forward-Looking Information

This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company, including the statements regarding: the partnership with Naturo will bring access to over 3,000 points of distribution as well as significant retail and e-commerce expertise; the beverage will be sold in traditional mass retail points of distribution and through direct to consumer e-commerce channels, expand BevCanna’s Anarchist Mountain brand into traditional points of retail and ecommerce, and will also allow BevCanna to sell product into Naturo’s extensive retail distribution network; Naturo’s significant and established distribution network will allow BevCanna to scale its retail distribution quickly and to leverage this network for its range of infused beverages; the full Anarchist Mountain brand portfolio will include non-cannabinoid options, including Beyond Energy, which will use hemp seed extract and which will be sold through traditional retail and ecommerce; as well as cannabis-infused options, which will be sold through licensed dispensaries; as domestic and international markets evolve regulations to allow for a broader distribution of cannabinoid based products, BevCanna will leverage the distribution network established through the non-cannabinoid options to broaden the distribution for cannabinoid infused beverages, consistent with their overall growth strategy of scaling into traditional points of retail to the maximize addressable market and leverage brand equity; and other statements regarding the business plans of the Company.

Forward-looking statements are based on certain assumptions regarding the issuances of licenses by Health Canada to the Company under the Cannabis Act; future positive legislative, tax and regulatory developments with respect to cannabis; a continued high regulatory barrier entry for cannabis-infused beverages; successful and timely commercialization of the company’s products; successful and timely negotiation of various agreements; and expectations with respect to the future growth of recreational cannabis products. While the Company considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. The assumptions of the Company, although considered reasonable by it at the time of preparation, may prove to be incorrect. In addition, forward-looking statements necessarily involve known and unknown risks, including, without limitation, the Company not being issued licenses by Health Canada; risks associated with general economic conditions; risks associated with climate and agriculture; changes in consumer preferences; adverse industry events; future legislative, tax and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the inability to implement business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. For more information on the risk, uncertainties and assumptions that could cause anticipated opportunities and actual results to differ materially, please refer to the public filings of the Company which are available on SEDAR at www.sedar.com. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law, and the Company does not assume any liability for disclosure relating to any other company mentioned herein.

For media enquiries or interviews, please contact:

Wynn Theriault, Thirty Dash Communications

416-710-3370

[email protected]

For investor inquiries, please contact:

Luca Leone, BevCanna Enterprises Inc.

604-880-6618

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Alternative Medicine Retail Health Fitness & Nutrition Specialty Food/Beverage

MEDIA:

Photo
Photo
Beyond Energy natural hemp energy drink (Photo: Business Wire)
Posted on

Willis Towers Watson acquires Acclimatise in move that further strengthens climate resilience leadership

Combining Acclimatise with WTW’s Climate and Resilience Hub creates global powerhouse for climate resilience services

LONDON, Nov. 12, 2020 (GLOBE NEWSWIRE) — Willis Towers Watson (NASDAQ: WLTW), a leading global advisory, broking and solutions company, today announced the acquisition of Acclimatise, the market leader in climate change adaptation advisory and analytics services, to meet growing demands from corporates, Governments and financial institutions.

Willis Towers Watson’s Climate and Resilience Hub (CRH) has expanded its scope to help clients address the challenges of climate and related Environmental, Social and Governance (ESG) issues across physical, transition and legal liability risks. Combining the capabilities of Acclimatise and the CRH will enhance the company’s leadership in physical climate risk and integrate this with a growing range of wider client services on climate and resilience.

Acclimatise, based in the UK with teams in France, the U.S. and India, brings a wealth of complementary experience in climate adaptation to Willis Towers Watson having completed over four hundred and fifty climate adaptation consulting projects since it was founded in 2004. The company has developed a unique platform to assimilate and apply climate model and earth observation data to support risk analytics and on-line applications. This has delivered a market leading position among financial services, natural resources, development institutions and Governments across developed and emerging markets to support national planning and climate finance.

Welcoming the deal, Rowan Douglas, Head of Willis Towers Watson’s Climate and Resilience Hub, said, “By combining Acclimatise’s market leading climate modelling and adaptation capabilities with Willis Towers Watsons’s deep experience in natural catastrophe modelling, risk management, re/insurance and investment markets we have a unique range of expertise to help clients manage climate exposures, seize adaptation opportunities and build more resilient societies and economies.”

“We have long admired Acclimatise and what John Firth and Dr. Richenda Connell have built as visionary leaders since 2004. Our earlier collaboration via the Willis Research Network illustrated a shared market ambition, culture and complementary experience and relationships. This feels like a very natural step for both teams. We are all excited about meeting the resilience challenges for corporates, Governments and financial institutions in the years ahead.”

John Haley, CEO at Willis Towers Watson, said “This acquisition is very much in line with our goal to help clients navigate an increasingly complex world and to achieve climate resilience through the provision of market-leading solutions. Acclimatise’s capabilities and proven success in the area of climate risk, provide significant opportunity for us going forward. I am excited about what this means for Willis Towers Watson.

In addition, combining the skillsets and capabilities of both companies will further strengthen our company’s efforts in addressing climate resilience for wider society, for example our work with the Coalition for Climate Resilient Investment (CCRI).”

John Firth, CEO and Co-Founder of Acclimatise, said, “Climate change risk is fast becoming a central part of government, corporate and financial decision making and planning. Meeting growing client demand will require increasingly sophisticated approaches to climate risk assessment and management. This is why I’m hugely excited by the potential that Willis Towers Watson’s acquisition of Acclimatise brings. I am very proud of Acclimatise’s achievements and our staff over its sixteen-year history – from kitchen table to a market leader – and am confident that combining with the Climate and Resilience Hub is the right move to ensure we can amplify the impact of our work.”

About Willis Towers Watson

Willis Towers Watson (NASDAQ: WLTW) is a leading global advisory, broking and solutions company that helps clients around the world turn risk into a path for growth. With roots dating to 1828, Willis Towers Watson has 45,000 employees serving more than 140 countries and markets. We design and deliver solutions that manage risk, optimize benefits, cultivate talent, and expand the power of capital to protect and strengthen institutions and individuals. Our unique perspective allows us to see the critical intersections between talent, assets and ideas — the dynamic formula that drives business performance. Together, we unlock potential. Learn more at willistowerswatson.com.

About the Climate and Resilience Hub

The Climate and Resilience Hub (CRH) is the focal point for our climate expertise and capabilities, pooling knowledge from across our people, risk and capital businesses and from our collaborations to deliver climate and resilience solutions in response to a range of regulatory, investor, consumer, employee and operating pressures. Under the Climate Quantified™ brand we deliver analytics, advice and transactions to enable corporate, finance and public sector institutions to embrace the climate decade ahead.

Media contact

Andrew Collis +44 (0) 7932 725267

Miles Russell +44 (0) 7903 262118

Posted on

NeoDynamics enters a scientific partnership to evaluate its technology platform in osteoarthritis

PR Newswire

STOCKHOLM, Nov. 12, 2020 /PRNewswire/ — NeoDynamics AB (publ), (Spotlight Stockholm: NEOD), today announced that the Company joins in a research collaboration with the William Hunter Revisited research consortium to evaluate NeoNavia pulse biopsy system for joint tissue sampling in a new potential indication, osteoarthritis.

The William Hunter Revisited research consortium consists of six universities and academic hospitals and is collaborating with industry to identify biomarkers and test new diagnostic devices for monitoring disease progression and repair as well as developing regenerative therapies for osteoarthritis.

“We look forward to collaborating with NeoDynamics and leveraging their expertise and technology to improve biopsy technique and tissue sampling in patients with osteoarthritis”, says Dr. Pieter Emans, Orthopedic Surgeon at Maastricht UMC.

“The collaboration with the consortium is a great opportunity for NeoDynamics, it gives us access to a network of leading clinicians and researchers in the field of osteoarthritis. Naturally we are interested to evaluate our technology platform beyond the breast cancer area”, says Kai-Uwe Schässburger, Ph.D. Director Clinical Development & Medical Affairs of NeoDynamics. “This will further validate our pulse biopsy system NeoNavia and explore the potential use in Osteoarthritis”.

Osteoarthritis is the most common form of arthritis, affecting more than 100 million patients around the world. It occurs when the protective cartilage that cushions the end of the bones gradually deteriorates and is the 4th leading cause of mobility-associated disability. Osteoarthritis is a degenerative disease that worsens over time often resulting in chronic pain. Societal costs are immense and reaching 15 Billion per year in the Netherlands alone. There is a significant need to developing innovative tools for tissue sampling, and analysis of disease progression to optimize individual treatment options.

The information was submitted for publication through the agency of the contact person set out below, at 08:55 CET on November 12, 2020

For additional information please contact: 

Anna Eriksrud, CEO NeoDynamics AB (publ). Phone +46 708 444 966 e-mail: [email protected]

Jörgen Vrenning, CFO/IR NeoDynamics AB (publ). Phone +46 708 519 648 e-mail: [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/neodynamics/r/neodynamics-enters-a-scientific-partnership-to-evaluate-its-technology-platform-in-osteoarthritis,c3235576

 

Cision View original content:http://www.prnewswire.com/news-releases/neodynamics-enters-a-scientific-partnership-to-evaluate-its-technology-platform-in-osteoarthritis-301171653.html

SOURCE NeoDynamics

Posted on

Epson Debuts First 8.5-Inch Desktop Dye-Sublimation Printer for Home or Small Businesses to Create and Sell Products Easily and Affordably

New Compact SureColor F170 Dye-Sublimation Printer Offers Turnkey Solution to Create Personalized Mugs, Face Masks, Mobile Phone Covers, T-Shirts, and More

PR Newswire

LOS ALAMITOS, Calif., Nov. 12, 2020 /PRNewswire/ –Epson today announced the first 8.5-inch wide desktop dye-sublimation printer – the SureColor® F170 – enabling creative individuals and small businesses to easily get started in the personalized promotional goods market. Designed to deliver fast, reliable dye-sublimation printing right out of the box, the new printer is ideal for home or small businesses and start-ups looking to expand their product offering into the gifting and promo goods sector. The new printer delivers an affordable and intuitive solution for creating personalized awards, mugs, mousepads, face masks, mobile phone covers, t-shirts, hats, and more.

“Americans are starting new businesses and shifting their product offerings at the fastest rate in more than a decade,” said Tim Check, senior product manager, Professional Imaging, Epson America, Inc. “As creative entrepreneurs and small businesses transition to meet new opportunities in a reshaped economy, there is an increased demand for entry-level dye-sublimation technology that allows customers to easily and confidently create and sell products. Whether you’re just getting started on Etsy or Shopify, or growing into new offerings, the SureColor F170 provides creative individuals and businesses everything needed to expand into the popular promotional goods market with a seamless solution built and fully supported by Epson.”

The purpose-built dye-sublimation printer delivers professional-quality prints using powerful PrecisionCore® technology. A truly turnkey solution, the SureColor F170 arrives with genuine Epson dye-sublimation ink technology, a 150-sheet auto-feed tray and macOS™ and Windows™ print software. The SureColor F170 offers fast turnaround times for product production and low running costs to home and small businesses and requires no specialist knowledge to set up, operate or maintain. In addition, the remarkably compact, space-saving design allows for maximized workshop space at home or in a small studio.

The SureColor F170 uses high-performance ink technology with OEKO-TEX® ECO PASSPORT certified inks which when applied to fabric and appropriately fixed, garments have been determined safe for use by adults, children and babies.1 The high capacity 140 mL bottles have auto-stop technology that allows for easy refilling without a mess. The SureColor F170 works with Epson DS Transfer Multi Use Paper, which is matched with print settings and ink to produce high-quality output out of the box. The instant dry paper avoids print smudges and roller marks and produces excellent photo quality on both rigid materials and fabrics.

The SureColor F170 delivers high image quality in one of the most compact, reliable dye-sublimation printers on the market. Additional features include:

  • Astounding print quality – PrecisionCore printhead offers Precision Droplet Control for outstanding clarity
  • Genuine Epson dye-sublimation ink technology – Delivers extraordinary color saturation and high color contrast
  • Versatile media support – Includes a 150-sheet auto-feed tray for added efficiency
  • Replace ink less often – High-capacity ink bottles with auto-stop for easy, mess-free filling
  • Tackle a variety of print jobs – Epson DS Transfer Multi Use Paper produces amazing images on both soft and rigid materials
  • Reliable performance – Backed by Epson world-class service and support
  • Easy printing right out of the box – Comes equipped with streamlined print software optimized for dye-sublimation
  • Flexible connectivity – Easily connect to the printer via USB, Ethernet or integrated wireless

Support and Availability
The Epson SureColor F170 will be available for $399 estimated MSRP through authorized Epson Professional Imaging resellers. The printer comes with a one-year, 15,000 page limited warranty. The printer is designed to work exclusively with Epson ink. For additional information, visit www.proimaging.epson.com.

About Epson
Epson is a global technology leader dedicated to becoming indispensable to society by connecting people, things and information with its original efficient, compact and precision technologies. The company is focused on driving innovations and exceeding customer expectations in inkjet, visual communications, wearables and robotics. Epson is proud of its contributions to realizing a sustainable society and its ongoing efforts to realizing the United Nations’ Sustainable Development Goals.

Led by the Japan-based Seiko Epson Corporation, the worldwide Epson Group generates annual sales of more than JPY 1 trillion. global.epson.com/

Epson America, Inc., based in Los Alamitos, Calif., is Epson’s regional headquarters for the U.S., Canada, and Latin America. To learn more about Epson, please visit: epson.com. You may also connect with Epson America on Facebook (facebook.com/Epson), Twitter (twitter.com/EpsonAmerica), YouTube (youtube.com/epsonamerica), and Instagram (instagram.com/EpsonAmerica).

* Epson strongly recommends the use of genuine ink to ensure optimal print quality and performance.

1 When applied to fabric and appropriately fixed Epson DS ink has passed the standards set by OEKO-TEX® ECO PASSPORT. For further details on these standards please visit www.oeko-tex.com/ecopass.

EPSON, PrecisionCore and SureColor are registered trademarks and EPSON Exceed Your Vision is a registered logomark of Seiko Epson Corporation. All other product and brand names are trademarks and/or registered trademarks of their respective companies. Epson disclaims any and all rights in these marks. Copyright 2020 Epson America, Inc.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/epson-debuts-first-8-5-inch-desktop-dye-sublimation-printer-for-home-or-small-businesses-to-create-and-sell-products-easily-and-affordably-301167812.html

SOURCE Epson America, Inc.

Posted on

Cardior Pharmaceuticals Announces Positive Phase Ib Results of its Lead Compound CDR132L in Heart Failure

  • First-in-class compound showed excellent tolerability and safety
  • Unique mode of action in chronic heart failure confirmed by data on cardiac function and biomarkers
  • Phase II studies in subacute and chronic heart failure
    planned

Hanover, Germany, November 12, 2020 – Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today positive results of a Phase Ib study with its lead compound CDR132L. The compound is an antisense oligonucleotide inhibiting the non-coding microRNA-132 (miR132) that directly regulates adverse cardiac remodeling. This first-in-human study was performed in cooperation with Richmond Pharmacology Ltd., London, UK (clinicaltrials.gov: NCT04045405). Results were published in the European Heart Journal (doi:10.1093/eurheartj/ehaa898).

In the trial, CDR132L met all endpoints and showed excellent tolerability and safety. The randomized, double-blind, placebo-controlled, dose-escalating study was designed to assess safety, pharmacokinetic (PK) and pharmacodynamic (PD) properties of CDR132L in patients with stable heart failure (HF) of ischemic origin (NYHA 1-3). The study design combined dose escalation with repeat dosing (day 1 and 28) at 4 dose levels. 28 patients received CDR132L or placebo (5:2 randomized in 4 cohorts) via short-term intravenous infusions as add-on therapy to standard of care.

Primary endpoint was safety and tolerability of CDR132L as assessed during the 120-day study period. The characterization of CDR132L’s PK profile in heart failure patients served as secondary endpoint. In addition, the effect of CDR132L on the target miR132 and on certain HF-relevant PD parameters was analyzed in an exploratory manner.

The infusion was very well tolerated by all patients with no injection-related signs. No safety signals or unexpected adverse events were observed for CDR132L. PK data showed strong dose-dependent linearity and specific target engagement could be confirmed. Exploratory analysis of multiple pharmacodynamic parameters, including measurement of NT-proBNP blood levels, showed beneficial effects on top of standard of care and will be used for planning Phase II proof-of-concept studies.

“CDR132L did not show any signs of toxicity regardless of dose level. As expected, the pharmacokinetic characteristics were found to be dose-dependently linear,” said Dr. Thomas Thum, Professor at Hannover Medical School and CSO of Cardior. “In addition, the target engagement data confirmed the mode of action of CDR132L. We also observed positive changes of various markers which in our preclinical models were strong signs of efficacy. In sum, the analysis of relevant surrogate pharmacodynamic parameters showed promising beneficial results in these patients, even after only two administrations of CDR132L.”

He added that the observed pharmacodynamic effects of CDR132L are planned to be further investigated in upcoming Phase II studies.

“We are very pleased with the outcome of our clinical study, the first-ever trial of an oligonucleotide-based drug in heart failure patients,” said Claudia Ulbrich, CEO of Cardior. “These encouraging results are an excellent basis for starting Phase II studies in subacute and chronic heart failure patients. The outcome of this trial also underlines the potential of RNA-based therapies as a causal approach to treat complex diseases.”

###

About CDR132L

CDR132L is an antisense oligonucleotide developed by Cardior Pharmaceuticals inhibiting the microRNA-132 (miR132), a non-coding microRNA that regulates cardiac hypertrophy and remodeling in cardiomyocytes by targeting well-defined pathways.

miR132 is a regulatory master switch to control cardiac function and a promising, causal therapeutic target in heart failure therapy. Expression of miR132 is increased in various pathological cardiac conditions in both animals and humans, and previous preclinical studies have shown that miR-132 is essential for driving the pathological growth of cardiomyocytes.

About Cardior

Cardior Pharmaceuticals is a privately held German biopharmaceutical company pioneering the development of curative and preventive heart failure therapeutics based on non-coding RNAs (ncRNAs). Cardior’s therapeutic approach is using distinctive ncRNA signatures driving the molecular reprogramming that causes maladaptive remodeling and heart failure. Drug candidates developed by Cardior represent first-in-class ncRNA therapeutics and diagnostics for patients with myocardial infarction and various forms of heart failure. Founded in 2016 based on the work of cardiologist Prof. Dr. Dr. Thomas Thum of Hannover Medical School, the Company has raised EUR 15 Mio. from international investors LSP, BioMedPartners, Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS) and High-Tech Gründerfonds (HTGF).

Contact Cardior

Dr. Claudia Ulbrich / Barbara Gaertner-Rupprecht
Cardior Pharmaceuticals GmbH
Feodor-Lynen-Str. 15
30625 Hanover
Germany
Tel: +49 511 33 85 99 30

Media Inquiries

akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
[email protected]
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

Posted on

Victory Square Technologies Portfolio Company Enters into Sales & Distribution Agreement for Safetest 15 Minute Covid-19 Rapid Test for North America with ProNorth Medical Corp.

  • Victory Square Health has entered into a new sales & distribution agreement with ProNorth Medical Corporation to provide its
    Safetest
    15 minute Covid-19 Rapid Testing kits in the United States of America and in Canada* following Health Canada approvals.
  • ProNorth Medical currently has multi-million dollar PPE products sales and distribution contracts with government, hospitals, and the private sector across North America.
  • North America has seen an additional 135,622 cases totaling 10,573,000 and 250,632 deaths from Covid-19 as of November 9, 2020
    (source: Code 19 Alert)
  • VSH Safetest Antibody Rapid Test products are critical because they identify if one has had or is currently infected with the Covid-19 virus.
    The end-user would know if previously infected with the virus, will have the antibodies present

VANCOUVER, British Columbia, Nov. 12, 2020 (GLOBE NEWSWIRE) — Victory Square Health Inc. (“VS Health” or the “Company“) – a portfolio company of Victory Square Technologies Inc. (“Victory Square”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) — is pleased to announce that it has entered into a sales & distribution agreement with ProNorth Medical, a North American Sales and Distribution Company, to sell its Safetest 15 minute Covid-19 Rapid Testing kits in the United States of America and in Canada* following Health Canada approvals.

ProNorth Medical has been proudly servicing Medical, Veterinary, and Dental professionals across North America for the past 9 years. ProNorth Medical CEO Robert Horne has a 30 plus year record in the medical sales and distribution sector, having worked with Johnson & Johnson for over 25 years prior to launching ProNorth Medical Corporation in 2011. ProNorth Medical currently has multi-million dollar Canadian and USA tested PPE products sales and distribution contracts with government, hospitals, and the private sector. ProNorth Medical clients in Canada include Hamilton Health Sciences Centre, The Ottawa Hospital, Vitalite Health Network, Service New Brunswick and Horizon Health. In addition, ProNorth Medical will engage with strategic film industry partners in the United States to provide major film studios, production companies, talent and crew with Safetest Covid-19 Testing products for detecting the antibodies IgG and IgM against SARS-CoV-2.

Pro North Medical associate, film producer and actor Cody Hackman who has produced films for Netflix, Lionsgate, MGM and many other companies says, “Our industry is anxiously waiting to safely resume pre-pandemic production volumes. Productions are finally starting to ramp up again but are now taking more time and are more costly due to Covid19. The Safetest Covid-19 Rapid Test from Victory Square Health will enable our industry to open up more quickly, safely, efficiently, and effectively to reduce the extra costs and production delays occurring due to Covid.”

“I am very pleased to have partnered with Victory Square Health to quickly and efficiently distribute and sell its Safetest Covid-19 suite of testing products to our network in the USA and hopefully soon throughout Canada with health approvals,” said Robert Horne, CEO ProNorth Medical. “Our Company has already received inquiries and requests/demand for the VSH Safetest Covid-19 Rapid test from our extensive network in America.”

Felipe Peixoto, CEO of VSH said, “The global vaccination process is a positive step towards tackling the world pandemic crisis, however, that will take many months if not years to cover the global population. Our Antibody Rapid Test products are critical in the process because they identify if one has had or is currently infected with the Covid-19 virus. By simply taking a drop of blood, the end-user, if previously infected with the virus, will have the antibodies present and know that he/she is not urgently required to take a vaccination.”

The Safetest 15 minute Covid-19 Rapid Testing kit enables the user to receive results with 96.6% sensitivity in 15 minutes by a simple blood sample similar to that of a hand held diabetes reader that resembles a pregnancy test stick. This highly accurate test enables the participant to quickly detect if they have Covid-19 antibodies in 15 minutes.

The Safetest 15 Minute Covid-19 Rapid Test has been granted permission by the Food & Drug Administration (FDA) in the United States to commence marketing, sales and distribution under the emergency use authorization (EUA). The Safetest 15 Minute Covid-19 Rapid Test has been approved for sale and distribution in the European Union and submitted for review and approval in Canada.

VS Health was founded in 2016 to accelerate the development of personalized medicine and technology solutions including diagnostic tests to support patient’s care and improve health outcomes. Its first product, the Leishmaniasis Rapid Test, was developed in partnership with the UFMG, Federal University of Minas Gerais. Safetest took advantage of its expertise in the subject to develop other antibody-based tests and a robust R&D pipelines of diagnostic kits for Hansen’s Disease, Brucellosis, HTLV and Blood samples screening tests.


Disclaimer:


The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time

Go to: VictorySquare.com and sign up for VST’s official newsletter at 


www.VictorySquare.com/newsletter

On behalf of the board,

Shafin Diamond Tejani
Chief Executive Officer
Victory Square Technologies

For further information about the Company, please contact:

Investor Relations Contact – Alex Tzilios
Email: [email protected]
Telephone: 778-867-0482

Media Relations Contact – Howard Blank, Director
Email: [email protected]
Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.

Victory Square (VST) builds, acquires and invests in promising startups, then provides the senior leadership and resources needed to fast-track growth.

VST’s sweet spot is the cutting-edge tech that’s shaping the 4th Industrial Revolution. Our portfolio consists of 20 global companies using AI, VR/AR and blockchain to disrupt sectors as diverse as fintech, insurance, health and gaming.

What we do differently for startups

VST isn’t just another investor. With real skin in the game, we’re committed to ensuring each company in our portfolio succeeds. Our secret sauce starts with selecting startups that have real solutions, not just ideas. We pair you with senior talent in product, engineering, customer acquisition and more. Then we let you do what you do best — build, innovate and disrupt. In 24-36 months, you’ll scale and be ready to monetize.

What we do differently for investors

VST is a publicly traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTCQX (VSQTF).

For investors, we offer early-stage access to the next unicorns before they’re unicorns.

Our portfolio represents a uniquely liquid and secure way for investors to get access to the latest cutting-edge technologies while also tapping into emerging global trends with big upsides. For more information, please visit www.victorysquare.com.

Forward Looking Statement

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the outlook of the business of Victory Square, including, without limitation, statements relating to future performance, execution of business strategy, future growth, business prospects and opportunities of Victory Square and its related subsidiaries, including Victory Square Health Inc., and other factors beyond our control. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, “continues”, “project”, “potential”, “possible”, “contemplate”, “seek”, “goal”, or similar expressions, or may employ such future or conditional verbs as “may”, “might”, “will”, “could”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements of historical facts contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

Posted on

Logitech Increases Use of Post-Consumer Recycled Plastic At Scale

Logitech Increases Use of Post-Consumer Recycled Plastic At Scale

By The End Of 2021, The Company’s Largest Product Portfolio Will Include Recycled Plastic In More Than 50 Percent Of All Mice And Keyboards Produced

LAUSANNE, Switzerland & NEWARK, Calif.–(BUSINESS WIRE)–
Logitech International (SIX: LOGN) (Nasdaq: LOGI), an award-winning design company and maker of cloud peripheral products, today announced its commitment to incorporating post-consumer recycled plastic (PCR) into its products at scale in an effort to reduce its carbon impact and increase circularity of consumer products. In a little over a year, the Company’s largest product portfolio will include PCR in more than 50 percent of its mice and keyboards, and will provide full transparency on the amount of PCR in each product to drive industry innovation and greater adoption of recycled plastic.

Tweet Now: By the end of 2021, more than 50% of mice & keyboards in Logitech’s largest product portfolio will use recycled plastic, eliminating an estimated 7,100 tons of virgin plastic and 11,000 tons of carbon per year. #SustainableDesign #CarbonReduction #Recycle

Over the last three years, Logitech has focused on increasingly moving to PCR plastic across its most popular product lines as part of its Design for Sustainability efforts. Since the launch of the PCR program, the Company will have shipped more than 50 million devices made with PCR plastic by the end of next year. Some products containing PCR plastic include the top-selling Logitech K120 and K400 keyboards, C390 webcam, M100 and M190 mice, and the UE HYPERBOOM. Logitech’s latest product made with PCR plastic is the new ERGO M575 mouse, which started with a design goal of maximizing the use of PCR plastic in the black, graphite and off-white model.

To drive carbon reduction at an even greater scale, Logitech is focusing on utilizing PCR plastic in products that account forthe most units sold globally. The Company is committing that by the end of 2021, more than 50 percent of the mice and keyboard produced in Logitech’s Creativity and Productivity portfolio, the Company’s largest portfolio, will be made with PCR plastic – eliminating an estimated 7,100 tons of virgin plastic and 11,000 tons of carbon per year.

“We are on a journey to design products for the future. The top area where we can make a significant and long-term impact to reduce carbon is by applying our design for sustainability principles across the product development process,” said Prakash Arunkundrum, Global Head of Operations and Sustainability at Logitech. “Since plastic is one of the most used materials at Logitech, we’re investing in the circular economy by recycling and reusing consumer products to push the limits of what is currently possible for recycled plastic.”

Increased Transparency

Starting with the ERGO M575, each product’s PCR content will be validated by independent, third-party experts and transparently shared on the Company’s website. The percentage of recycled plastic in each product will vary depending on the type, color and material make up of a product. The percent of a product’s plastic parts made of PCR currently range from 80% PCR content to no less than 20% for the technically complex lighter color products. Logitech’s design goal is to continue to maximize the percentage of recycled content in each product.

“We congratulate Logitech’s commitment to transparency and third-party certification of post-consumer recycled plastic,” said Nicole Muñoz, Vice President of Environmental Certification Services at SCS Global Services. “Logitech’s focus on circularity and the incorporation of recycled content into their products demonstrates leadership in the consumer electronics industry.”

Innovation

Logitech is working with plastic suppliers to design new and stronger resins in a range of new colors, expanding on what is possible today. New resins will be used in Logitech products to give consumers more color options without compromising on product quality, while also being made available to other companies in an effort to help reduce the consumer electronics industry’s carbon impact.

Beyond recycled plastics, Logitech is working with external partners to develop a roadmap of sustainable materials for the future, as well as sustainable packaging advancements, ongoing innovation on making lower impact electronic devices and continuing to drive renewable electricity programs.

To learn more about Logitech’s Designing for Sustainability and Recycled Plastic efforts, please visit www.logitech.com/sustainability.

About Logitech

Logitech designs products that have an everyday place in people’s lives, connecting them to the digital experiences they care about. More than 35 years ago, Logitech started connecting people through computers, and now it’s a multi-brand company designing products that bring people together through music, gaming, video, and computing. Brands of Logitech include Logitech, Logitech G, ASTRO Gaming, Streamlabs, Ultimate Ears, Jaybird and Blue Microphones. Founded in 1981, and headquartered in Lausanne, Switzerland, Logitech International is a Swiss public company listed on the SIX Swiss Exchange (LOGN) and on the Nasdaq Global Select Market (LOGI). Find Logitech at www.logitech.com, the company blog or @Logitech.

Logitech and other Logitech marks are trademarks or registered trademarks of Logitech Europe S.A. and/or its affiliates in the U.S. and other countries. All other trademarks are the property of their respective owners. For more information about Logitech and its products, visit the company’s website at www.logitech.com.

(LOGIIR)

Nicole Kenyon

Head of Global Corporate & Employee Communications – USA

+1 (510) 988-8553

Ben Starkie

Corporate Communications – Europe

+41 (0) 79-292-3499

KEYWORDS: Europe Switzerland United States North America California

INDUSTRY KEYWORDS: Chemicals/Plastics Consumer Electronics Technology Manufacturing Software Hardware

MEDIA:

Logo
Logo
Posted on

Digital Locations to Benefit from Augmented Reality (AR) and Virtual Reality (VR) Applications Driving the Growth of 5G

Microsoft’s HoloLens 2 adds 5G support for AR, but widespread adoption will require transmission in the true 5G super high-speed millimeter-wave (mmWave) spectrum.

SANTA BARBARA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Digital Locations, Inc. (DLOC), a developer of cell tower sites for the 5G revolution, today announced that it is likely to benefit from the growth of 5G small cell sites driven by Augmented Reality (AR) and Virtual Reality (VR) applications that require super high-speed transmission.

“Augmented reality and virtual reality have suddenly become more relevant in a world where people can’t meet in person as easily,” said Bill Beifuss, President of Digital Locations. “Devices such as Microsoft’s HoloLens 2 are prime examples of applications that will drive the growth of 5G services.”

HoloLens 2 users touch, grasp, and move holograms in ways that feel natural – they respond a lot like real objects – resulting in a comfortable and immersive mixed reality experience.

See the video demonstrating Microsoft’s HoloLens 2 augmented reality device:
https://www.youtube.com/watch?v=uIHPPtPBgHk

Holograms have the potential to dramatically improve training, design, and visualization in many business settings and production facilities. Being able to look at, zoom in on and manipulate 3D versions of in-progress designs radically enhances the design process. And voice commands work even in noisy industrial environments through smart microphones and natural language speech processing.

In the field of education, holograms are very important. The reason is that students can actually view the concepts that are taught and visualize them in class or from a distance. Holograms will help students clarify concepts more readily and will enhance the way they learn.

All of these exciting AR applications are only possible with high speed and low latency wireless data transmission. 5G wireless technology can provide that and 5G small cell networks are essential parts of the high speed, low latency solution. The FCC expects up to 80% of new cell site deployments will be small cells. That is because small cells are the only way for operators to deploy 5G in the super high-speed millimeter-wave (mmWave) spectrum. Transmissions in mmWave spectrum can only travel a few hundred feet, due to the propagation characteristics of that band, and that is ideal for small cells simply because they can be as small as a pizza box and are often installed on building roof tops, store fronts and so-called “street furniture” like light poles or streetlights.

At this time, there is no indication that the large wireless operators, such as Verizon, AT&T and T-Mobile Sprint, plan to heavily invest in building small cell networks throughout the country. Instead, they are seeking partners to facilitate the buildout of these networks.

Mr. Beifuss concluded, “All these factors point to a very large market for small cells and a substantial opportunity for Digital Locations. To minimize upfront capital costs, Digital Locations plans to enter into lease option agreements with building/property owners. Once an adequate number of sites have been secured in a particular area (perhaps 20-25 locations in a square mile area), the Company will enter into rental agreements with one or more large wireless operators desiring to extend 5G coverage in the area.”

About Digital Locations, Inc.

Digital Locations, Inc., is a developer of cell tower sites for the 5G revolution. 5G wireless networks are expected to be 100 times faster than current 4G LTE networks. This will enable global scale killer applications such as self-driving cars, the Internet of things (IOT), mobile streaming of 4K videos, real-time hologram-based collaboration, and lag-free high definition gaming. To realize this vision, many new 5G antennas are needed because high frequency 5G signals cannot travel farther than 100 meters. It is estimated that more than 1 million new 5G cell towers must be added in the United States alone. To rapidly enter the market, Digital Locations plans to partner or co-develop a portfolio of cell tower sites to help meet the demands of 5G networks. Our goal is to become a “landlord” of tomorrow’s wireless communications assets.

To learn more about Digital Locations please visit www.digitallocations.com 

Safe Harbor
Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein, and while expected, there is no guarantee that we will attain the aforementioned anticipated developmental milestones. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.

Press Contact:
[email protected]
(805) 456-7000

Posted on

iClick Interactive to be Added to the MSCI China Small Cap Index

PR Newswire

HONG KONG, Nov. 12, 2020 /PRNewswire/ — iClick Interactive Asia Group Limited (“iClick” or the “Company”) (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, announced today that the Company’s stock will be added to the MSCI China Small Cap Index, effective as of market close on November 30, 2020. 

The MSCI China Small Cap Index is compiled by MSCI Inc., a leading provider of research-based indexes and analytics, announced the results of the November 2020 Semi-Annual Index Review for the MSCI Equity Indexes – including the MSCI China Small Cap Index. It is designed to measure the performance of the small cap segment of the China market. The index has been widely recognized as a benchmark for global institutional investors to optimize their investment portfolios.

About iClick Interactive Asia Group Limited

iClick Interactive Asia Group Limited (NASDAQ: ICLK) is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, our proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide including Asia and Europe.

For more information, please visit ir.i-click.com.

Safe Harbor Statement

This announcement contains forward-looking statements, including those related to the Company’s business strategies, operations and financial performance. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such statements are based upon management’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s fluctuations in growth; its success in implementing its mobile and new retail strategies, including extending its solutions beyond its core online marketing business; its success in structuring a CRM & Marketing Cloud platform; relative percentage of its gross billing recognized as revenue under the gross and net models; its ability to retain existing clients or attract new ones; its ability to retain content distribution channels and negotiate favorable contractual terms; market competition, including from independent online marketing technology platforms as well as large and well-established internet companies; market acceptance of online marketing technology solutions and enterprise solutions; effectiveness of its algorithms and data engines; its ability to collect and use data from various sources; ability to integrate and realize synergies from acquisitions, investments or strategic partnership; fluctuations in foreign exchange rates; and general economic conditions in China and other jurisdictions where the Company operates; and the regulatory landscape in China and other jurisdictions where the Company operates. Further information regarding these and other risks is included in the Company’s annual report on Form 20-F and other filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:


In China:


In the United States:


iClick Interactive Asia Group Limited


Core IR

Lisa Li

Tom Caden

Phone: +86-21-3230-3931 #892

Tel: +1-516-222-2560

E-mail: [email protected]

E-mail: [email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/iclick-interactive-to-be-added-to-the-msci-china-small-cap-index-301171639.html

SOURCE iClick Interactive Asia Group Limited

Posted on

Nokia and Deutsche Telekom Group expand strategic cooperation to build 5G-ready IP network

Press Release

Nokia and Deutsche Telekom Group expand strategic cooperation to build
5G-ready IP network

          

  • Deutsche Telekom will deploy the Nokia 7750 Service Router portfolio, designed for the 5G and cloud era, to replace and modernize its existing IP edge/core network in Greece and Hungary initially
     
  • Nokia’s IP edge routers deliver the high-performance, scale and flexibility to support a full array of IP services and functions that meet evolving end user needs

          
12 November 2020

Espoo, Finland – Nokia and Deutsche Telekom Group today announced they are expanding their strategic cooperation to build a 5G-ready IP network. Deutsche Telekom has selected Nokia’s 7750 Service Router (SR) platform to significantly expand capacity across its edge/core routing network as it prepares for next-generation broadband and 5G services. Deployment has already started in Greece, where Nokia is replacing and modernizing the operator’s existing IP network. Rollout in Hungary is expected in Q4 2020.

With networks experiencing unprecedented traffic growth and unpredictable demands, operators want to meet ever-increasing performance requirements while driving down network costs. The scale, feature breadth and versatility of the Nokia 7750 SR-s platform addresses these requirements, enabling operators like Deutsche Telekom Group and its affiliates to build bigger, smarter, automated and secure networks with greater return on investment.

As part of its network modernization, Deutsche Telekom needed to replace an existing IP edge/core network that was reaching its end of service with a new network that can cope with 5G and ultra broadband access requirements. A key principle to achieve this was the consolidation of network layers through the integration of IP aggregation and edge/BNG (Broadband Network Gateway) functions into one converged layer.

Deutsche Telekom selected the Nokia 7750 SR-7s routers as they support the full spectrum of provider edge, gateway and core functions for advanced residential, mobile and enterprise services. Powered by the programmable FP4 network processing silicon, the routers will enable Deutsche Telekom to boost IP network capacity with deterministic performace for a top-quality subscriber experience. As a result, Deutsche Telekom can support 5G interconnectivity and an increasing growth in backbone traffic driven by an increase in mobility applications, video streaming, gaming and other high-capacity demands such as remote working.

The 7750 SR-s is managed by the Nokia Network Services Platform (NSP). NSP supports 5G IP transport with automated slicing across IP and optical transport layers with end-to-end orchestration of network resource provisioning and assurance operations. This simplifies operations so that operators can create customer policies/slices with different network performance, quality and routing capabilities to respond quickly to fast-changing subscriber demand.

Bernhard Scholl, Technology Europe VP Access Core & Transport at Deutsche Telekom, said: “Deutsche Telekom Group affiliates need to expand and modernize their IP networks to address stringent 5G IP transport requirements. We continue to see tremendous growth in network traffic and the need to deliver more throughput and higher capacity with strict QoS to our customers is critical. This is particlarly the case as bandwidth intensive applications are shifting to on demand video along with the growing usage of cloud-based services. Building out this backbone with Nokia’s IP edge routers will allow us to stay ahead of our customers’ network needs.”

Vassilis Kazatzopoulos, Head of International Sales DT Global Customer Business Team at Nokia, said: “With trends like 5G, IoT and Industry 4.0 now a reality, networks are expected to handle hundreds of new applications and services for millions of users. The Nokia 7750 SR-s series of IP routers takes router performance to the next level by delivering the massive scale, comprehensive feature set and platform versatility needed to stay ahead of evolving demands. Nokia is excited to expand its longstanding relationship with Deutsche Telekom Group to help prepare its affiliates’ networks for the future.”

Resources:

About Nokia

We create the technology to connect the world. Only Nokia offers a comprehensive portfolio of network equipment, software, services and licensing opportunities across the globe. With our commitment to innovation, driven by the award-winning Nokia Bell Labs, we are a leader in the development and deployment of 5G networks.

Our communications service provider customers support more than 6.4 billion subscriptions with our radio networks, and our enterprise customers have deployed over 1,300 industrial networks worldwide. Adhering to the highest ethical standards, we transform how people live, work and communicate. For our latest updates, please visit us online www.nokia.com and follow us on Twitter @nokia.

Media Inquiries:

Nokia
Communications
Phone: +358 10 448 4900
Email: [email protected]